Relugonat 120mg Tablet

Relugonat 120mg tablet is a prescription based medication. It is used to treat advanced prostate cancer in men by lowering testosterone levels and slows the growth or spread of cancer cells in the body. Its active ingredient is Relugolix which belongs to the drug class of gonadotropin- releasing hormone (GnRH) receptor antagonist.

By directly blocking GnRH receptors, it rapidly reduces testosterone without causing an initial hormone surge, helping to better control cancer progression. The medication is only recommended to patients above the age of 18. Follow the dose as directed by the healthcare professional.

• Treat prostate cancer

Relugonat 120mg tablet show several side effects, some may resolve on their own while requires proper medical attention. Some of the symptoms include:

• Tiredness
• Constipation
• Diarrhea
• Dizziness
• Headache
• Nausea
• Rash
• Fatigue
• low red cell count (anemia)
• Breast enlargement in men (gynecomastia)
• Hot flushes
• Increased blood sugar levels
• Increased blood fat (triglyceride) levels
• Muscle and joint pain
• Decreased blood hemoglobin levels
• Increased liver enzymes

• Relugonat 120mg tablet should be taken under doctor prescription. It can be taken with or without food at the same time everyday to enhance the effectiveness of the treatment.
• Do not miss or overdose the medication as it affect the patient overall health and effectiveness of cancer control. Missed dose always taken under the healthcare professional to ensure safe treatment.
  

• Relugonat 120mg tablet works by blocking the testosterone hormone as it is responsible in the formation of cancer cells which results in spreading of prostate cancer to other parts of the body.
• It acts by directly blocking gonadotropin releasing hormone (GnRH) receptors in the pituitary gland which reduces the release of luteinizing hormone and ultimately suppresses testosterone production. It helps control tumor growth without causing an initial rise in testosterone level.
  

• Shore, N. D., Saad, F., Cookson, M. S., George, D. J., Saltzstein, D. R., Tutrone, R., ... & Tombal, B. (2020). Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. New England Journal of Medicine, 382(23), 2187-2196. https://pubmed.ncbi.nlm.nih.gov/32469183/
• Shirley, M. (2023). Relugolix: a review in advanced prostate cancer. Targeted Oncology, 18(2), 295-302. https://pubmed.ncbi.nlm.nih.gov/36652173/
• Spratt, D. E., George, D. J., Shore, N. D., Cookson, M. S., Saltzstein, D. R., Tutrone, R., ... & Tombal, B. F. (2024). Efficacy and safety of radiotherapy plus relugolix in men with localized or advanced prostate cancer. JAMA oncology, 10(5), 594-602. https://pubmed.ncbi.nlm.nih.gov/38451492/
• Al-Hendy, A., Lukes, A. S., Poindexter III, A. N., Venturella, R., Villarroel, C., Critchley, H. O., ... & Stewart, E. A. (2021). Treatment of uterine fibroid symptoms with relugolix combination therapy. New England Journal of Medicine, 384(7), 630-642. https://pubmed.ncbi.nlm.nih.gov/33596357/
• Saad, F., & Shore, N. D. (2021). Relugolix: a novel androgen deprivation therapy for management of patients with advanced prostate cancer. Therapeutic Advances in Medical Oncology, 13, 1758835921998586. https://pubmed.ncbi.nlm.nih.gov/34408793/